Literature DB >> 18928444

Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.

Musa Drini1, Peter J Prichard, Gregor J E Brown, Finlay A Macrae.   

Abstract

Tumour necrosis factor inhibitors have revolutionised the management of Crohn's disease, but reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (a rare form of aggressive non-Hodgkin's lymphoma) have emerged. We describe the first case in Australia of hepatosplenic T-cell lymphoma in a patient who had been treated with infliximab and immunomodulators for Crohn's disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18928444     DOI： 10.5694/j.1326-5377.2008.tb02124.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  8 in total

Review 1.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

2.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

3.  Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

Authors:  Eric D Shah; Elliot S Coburn; Anil Nayyar; Kerry Jo Lee; Jenna L Koliani-Pace; Corey A Siegel
Journal:  Aliment Pharmacol Ther       Date:  2020-01-28       Impact factor: 8.171

4.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

5.  Hepatosplenic T cell lymphoma presenting as multiorgan failure.

Authors:  Puraskar Pateria; Annalise Martin; Tze Sheng Khor; Vanoo Jayasekeran
Journal:  BMJ Case Rep       Date:  2019-03-21

Review 6.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

7.  Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis.

Authors:  Qian Zhang; Hong Y Wang; Gauri Bhutani; Xiaobin Liu; Michele Paessler; John W Tobias; Donald Baldwin; Kunchithapadam Swaminathan; Michael C Milone; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

8.  Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.

Authors:  Saranya A Selvaraj; Elizabeth Chairez; Lisa M Wilson; Mark Lazarev; Eric B Bass; Susan Hutfless
Journal:  Syst Rev       Date:  2013-07-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.